Rebecca Schmidt, DO
Nephrology · Morgantown, WVNPI 1972617488
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,500 of the $4,822 with a category attached, or 93.3%. Outset Medical Inc accounts for 94.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $4,663 and has fallen 99.4% since, to $28 in 2025.
Across 10 payments — averaging $482.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Outset Medical Inc$5K
- OPKO Pharmaceuticals, LLC$154
- AstraZeneca$35
- Mallinckrodt Hospital Products Inc.$30
- Nxstage Medical, Inc.$28
Across 37 payments — averaging $1885.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$30K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$23K
- AstraZeneca$13K
- AbbVie$4K
What the payments were for
- Consulting fees$4,50093%
- Food & beverage$3227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Outset Medical Inc | 3 | $4,575 |
| OPKO Pharmaceuticals, LLC | 4 | $154 |
| AstraZeneca | 1 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Nxstage Medical, Inc. | 1 | $28 |
How this compares
$4,822 in reported general payments places this provider in the 80th percentile of 55 nephrology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 30 | $72,904 |
| AuryxiaFerric Citrate | 30 | $56,415 |
| LinzessLinaclotide | 14 | $9,176 |
| Sevelamer Carbonate | 32 | $1,950 |
| Gentamicin Sulfate | 17 | $592 |
| Terazosin Hcl | 46 | $544 |
| Torsemide | 11 | $506 |
| Omeprazole | 11 | $271 |
| Ropinirole Hcl | 15 | $214 |
| Furosemide | 15 | $118 |
| Sertraline Hcl | 14 | $108 |
| Potassium Chloride | 11 | $84 |
| Losartan Potassium | 20 | $69 |
| Amlodipine Besylate | 11 | $47 |
| Gabapentin | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Morgantown
- Arijit ChakravartyMorgantown$19K
- Adeem AkbarMorgantown$740
- Anas DiabMorgantown$482
- Anthony ParravaniMorgantown$166
- Bethany PellegrinoMorgantown$160
- Jennifer BergeronMorgantown$124
- Dinesh Kumar KannabhiranMorgantown$117
- Vijay VidyasagarMorgantown$40
- Sana AkbarMorgantown$34
- Mark PolingMorgantown$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.